Takeda Pharmaceutical Co. Ltd. said FDA has approved the supplemental new drug application for Alunbrig (brigatinib) 180 mg tablets.
Genentech, a member of the Roche Group, said FDA has accepted the company's supplemental Biologics License Application and granted Priority Review for Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant treatment of HER2-positive early breast cancer.
Mylan N.V. announced the U.S. launch of Imatinib Mesylate Tablets, 100 mg and 400 mg, a generic version of Novartis's Gleevec Tablets.
Amgen and CytomX Therapeutics Inc. have entered into a collaboration in immuno-oncology that will allow the companies to co-develop a CytomX Probody T-cell engaging bispecific against the epidermal growth factor receptor. Probody T-cell engaging bispecifics are antibody constructs capable of directing cytotoxic T-cells in tumor microenvironments. In preclinical studies, CytomX’s Probody versions of EGFRxCD3 bispecific […]
Sunil Sharma, joined the Translational Genomics Research Institute, pursuing drug development and patient clinical trials in concert with TGen's research alliance with City of Hope in California, and TGen's clinical partnership with the HonorHealth Research Institute in Scottsdale.
An item in the newly passed Wisconsin state budget will expand a collaborative network of the UW Carbone Cancer Center and cancer doctors around the state to help find treatments matched to the genetic differences in patients' cancer.
By Emily RubinNovelistWe see the brightness of a new page where anything yet can happen.Rainer Maria RilkeI was diagnosed with breast cancer in 2008 and underwent treatment until 2010 at Beth Israel Hospital, now Mount Sinai, in New York. A year after finishing treatment I was thrilled to find out that my novel, Stalina, was a winner of the Amazon Debut Novel Award Contest.
Through the controversies triggered by the National Dialogue on Cancer, John Seffrin relied on his ACS ally Allan Erickson.
The Foundation for Tobacco-Free World is unlikely to win hearts and minds in the tobacco control community, said Matt Myers, president of the Campaign for Tobacco-Free Kids.
In January 2000, The Cancer Letter was working on a story about what seemed to be a strange political structure that was being put together by the American Cancer Society.
